[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-328345-105":59,"doc-detail-328345-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","multicenter-proteome-wide-mendelian-randomization-study-identifies-causal-plasma-proteins-in-melanoma-and-non-melanoma-skin-cancers","Multicenter proteome-wide Mendelian randomization study identifies causal plasma proteins in melanoma and non-melanoma skin cancers","","A multicenter Mendelian randomization framework identifies circulating plasma proteins causally linked to malignant melanoma and non-melanoma skin cancer traits. Large-scale cis-MR estimates protein effects across MM, NMSC, squamous cell carcinoma, and basal cell carcinoma, with robustness supported by MR Steiger, Bayesian colocalization, and replication via meta-analytical methods. Tissue-level validation uses Transcriptome-Wide Association Study analyses, followed by protein-protein interaction profiling to connect prioritized proteins with existing cancer drug targets. The MR results implicate 13 proteins for BCC, 2 for SCC, and 1 for MM, nominating ASIP, KRT5, CTSS, and TNFSF8 as diagnostic and therapeutic candidates.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/multicenter-proteome-wide-mendelian-randomization-study-identifies-causal-plasma-proteins-in-melanoma-and-non-melanoma-skin-cancers/328345/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/multicenter-proteome-wide-mendelian-randomization-study-identifies-causal-plasma-proteins-in-melanoma-and-non-melanoma-skin-cancers/328345.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the multicenter Mendelian randomization study?","Question",{"text":112,"@type":113},"To identify circulating plasma proteins that are causally associated with traits of malignant melanoma and non-melanoma skin cancers using integrated GWAS and pQTL data.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is causal evidence strengthened in the study?",{"text":117,"@type":113},"By using large-scale cis-MR and performing additional robustness analyses such as MR Steiger and Bayesian colocalization, then replicating findings through meta-analytical methods.",{"name":119,"@type":110,"acceptedAnswer":120},"Which plasma proteins are highlighted as potential diagnostic and therapeutic targets?",{"text":121,"@type":113},"ASIP, KRT5, CTSS, and TNFSF8 are nominated as potential targets based on the multidimensional analyses, including protein-protein interaction and druggability considerations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},328345,1790726399,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","communications biology Article  \n[https://doi.org/10.1038/s42003-024-06538-2](https://doi.org/10.1038/s42003-024-06538-2)  \nMulticenter proteome-wide Mendelian randomization study identifies causal plasma proteins in melanoma and non-melanoma skin cancers  \n Check for updates  \nYajia Li  1,2, Qiangxiang Li2, Ziqin Cao 2,3,4  & Jianhuang Wu 2,3,4   \nThis study addresses the diagnostic and therapeutic challenges in malignant melanoma (MM) and non-melanoma skin cancers(NMSC). We aim to identify circulating proteins causally linked toMMand NMSC traits using a multicenter Mendelian randomization (MR) framework. We utilized large-scale cis-MR to estimatethe impact of numerous plasma proteins on MM, NMSC, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC). To ensure robustness, additional analyses like MR Steiger and Bayesian colocalization are conducted, followed by replication through meta-analytical methods. The associations between identified proteins and outcomes are also validated at the tissue level using Transcriptome-Wide Association Study methods. Furthermore, a protein-protein interaction analysis is conducted to explore the relationship between identified proteins and existing cancer medication targets. The MR analysis has identified associations of 13 plasma proteins with BCC, 2 with SCC, and 1 with MM. Specifically, ASIP and KRT5 are associated with BCC, with ASIP also potentially targeting MM. CTSS and TNFSF8 are identified as promising druggability candidates for BCC. This multidimensional approach nominates ASIP, KRT5, CTSS, and TNFSF8 as potential diagnostic and therapeutic targets for skin cancers.  \nSkin cancer is the fifth most common cancer type and rates are predicted to rise sharply over the next 20 years1–4. Malignant melanoma (MM) arises when mutations occur in melanocytes. It is highly invasive and metastatic and accounts for around 75% of skin cancer-related deaths despite representing only 4% of all skin cancers5,6. Non-melanoma skin cancer (NMSC) develops from the epidermis and may be subdivided into squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). It is the most frequently occurring form of skin cancer and is considered curable at an early stage, although the identification of novel drugs, clinical success, and drug resistance present challenges7. On the one hand, traditionally, screening via imaging and pathology tests has had limited effectiveness in early-stage detection. On the other hand, until date, the main treatments for MM and NMSC, including surgery, chemotherapy, radiotherapy, photothermal therapy, etc, are often painful and can have negative consequences, rarely resulting in cancer eradication8,9. Current treatments often fail to specifically target cancer cells, resulting in only modest extensions in survival for  \nadvanced MM or NSMC patients1, 10–13. Such therapies frequently impact healthy cells without adequately targeting cancerous ones13–15. Skin cancer’s complexity and cellular heterogeneity lead to varied progression and metastasis, driven by the dysregulation at multiple targeting sites. Recent advancements in targeted therapies offer promising alternatives, utilizing drugs that directly inhibit specific molecules or pathways critical to cancer cells, like BRAF16. However, the myriad skin cancer subtypes and emerging drug resistances continue to complicate achieving a comprehensive cure with a single therapeutic approach17, 18. Therefore, developing innovative strategies for early detection and treatment remains critical to addressing these challenges in managing MM and NSMC.  \nPlasma proteins mediate signaling, transportation, growth, repair, and defense against infections. Many are also cancer biomarkers, enabling early diagnosis, prognostic evaluation, and treatment monitoring19,20. Immune checkpoint inhibitors (ICIs) are effective in treating MM and NMSC but only a small proportion of patients respond to them21–24. Biomarkers, such as  \n1Department of Dermatology,","cbCaioz17rs5Ps2C","https://ap.wps.com/l/cbCaioz17rs5Ps2C","pdf",1551869,13,"English","# Introduction\n## Background and clinical challenges\n## Rationale for protein biomarkers\n# Methods\n## Mendelian randomization framework\n## Validation and druggability analyses\n# Results\n## Causal proteins by cancer subtype","[{\"question\":\"What is the main goal of the multicenter Mendelian randomization study?\",\"answer\":\"To identify circulating plasma proteins that are causally associated with traits of malignant melanoma and non-melanoma skin cancers using integrated GWAS and pQTL data.\"},{\"question\":\"How is causal evidence strengthened in the study?\",\"answer\":\"By using large-scale cis-MR and performing additional robustness analyses such as MR Steiger and Bayesian colocalization, then replicating findings through meta-analytical methods.\"},{\"question\":\"Which plasma proteins are highlighted as potential diagnostic and therapeutic targets?\",\"answer\":\"ASIP, KRT5, CTSS, and TNFSF8 are nominated as potential targets based on the multidimensional analyses, including protein-protein interaction and druggability considerations.\"}]","Multicenter proteome-wide Mendelian randomization study identifies causal plasma proteins in melanoma and non-melanoma skin cancers | PDF",1789979396,33]